(RTTNews) - Tvardi Therapeutics, Inc. (TVRD) reported fourth-quarter and full-year 2025 financial results and highlighted progress across its STAT3-targeted pipeline, including upcoming data readouts for both its next-generation inhibitor TTI-109 and its lead candidate TTI-101.
2 views
Tvardi Therapeutics Narrows FY25 Loss, Prepares For Key STAT3 Clinical Readouts In 2026
(RTTNews) - Tvardi Therapeutics, Inc. (TVRD) reported fourth-quarter and full-year 2025 financial results and highlighted progress across its STAT3-targeted pipeline, including upcoming data readouts for both its…
